It’s not a simple cliché or abstraction to state, for the record, that the best, most profitable, and most enduring business plan is simply, and above all else, doing the best for the patient. Hence, when considering the economics of PROKERA® use in practice, we must ensure that we are making calculations based on the appropriate metrics. Are we considering only the myopic calculation of price and profit-margin; erroneously rationalizing that an amniotic membrane is an amniotic membrane?
Or, are we, our patients, and our long-term practice prospects, better off, by focusing on endpoints like quality of healing, speed of healing, and the other metrics of efficiency, time, and profitability that they directly and indirectly impact? In this blog, I will address the rationale (both economic and medical) behind our decision to use the PROKERA-line in my Cornea, Cataract, and Refractive practice.